365 related articles for article (PubMed ID: 23602735)
1. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
2. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
3. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
4. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Liu R; Liu D; Xing M
J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
6. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
J Clin Endocrinol Metab; 2009 Oct; 94(10):4107-12. PubMed ID: 19723757
[TBL] [Abstract][Full Text] [Related]
10. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
[TBL] [Abstract][Full Text] [Related]
11. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
16. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
17. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Zhong H; Sanchez C; Spitzer D; Plambeck-Suess S; Gibbs J; Hawkins WG; Denardo D; Gao F; Pufahl RA; Lockhart AC; Xu M; Linehan D; Weber J; Wang-Gillam A
PLoS One; 2013; 8(10):e77243. PubMed ID: 24130864
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
20. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.
Barollo S; Bertazza L; Baldini E; Ulisse S; Cavedon E; Boscaro M; Pezzani R; Mian C
Invest New Drugs; 2014 Aug; 32(4):626-35. PubMed ID: 24821574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
